FU Wei (Panelist)
CEO, CBC Group
Mr. Fu Wei is CEO of CBC Group, the largest healthcare dedicated investment firm in Asia, with more than US$2.7 billion AUM under management across five offices in Shanghai, New York, Beijing, Hong Kong and Singapore.
I-Mab Biopharma and Everest Medicines are two portfolio companies incubated from scratch by CBC Group, which listed on NASDAQ and Hong Kong Stock Exchange respectively this year, generating more than 2 billion U.S. dollars income for CBC Group, establishing new standards and innovation in the field of healthcare investment at the same time.
Before founding CBC Group, Mr. Fu Wei worked in principle private equity investment at Temasek, Goldman Sachs, Standard Chartered and Far East Horizon.
KUAN Chee Mun (Panelist) '05
Executive Director and Co-Founder, AIM Biotech Pte. Ltd.
Mr. Kuan Chee Mun is the Executive Director of AIM Biotech, a Singapore-based company commercialising an organ-on-a-chip platform invented at MIT. Before starting AIM Biotech as its cofounding CEO, Kuan Chee Mun was previously responsible for Advanced Technology Development at Becton Dickinson & Co. (Asia-Pacific), a Fortune 500 medical device multinational company. He focused on identifying new business opportunities and developing product concepts & technologies to address unmet needs of customers from China, India and other Asia Pacific economies. Prior to this appointment, Chee Mun was the General Manager for the first international subsidiary of the Johns Hopkins University School of Medicine, based in Singapore. He began his career in academic research in molecular biology, and later joined the Singapore National Science & Technology Board.
Chee Mun holds an MBA from the University of Chicago Booth School of Business and a Bachelor of Science (Honours) in Cell & Molecular Biology from the National University of Singapore.
P.C. ZHU (Speaker) '11
Founder and CEO, ATLATL Innovation Cluster
Dr. Zhu is the Founder and CEO of ATLATL Innovation Center, the largest shared Class A research space in the world. Before ATLATL, Dr. Zhu initiated and co-founded Mass Innovation Labs in Boston. His laboratories incubated many leading biotech companies, including CRISPR, C4, Editas, Gritstone, CUE, TCR2, and Oncorus, most of which achieved an IPO in 3 years.
Dr. Zhu brings a strong track record of entrepreneurial and operational expertise in the life sciences. His entrepreneurial achievements include founding NEO, life sciences CRO, and co-founding GENEE Scientific, a life science informatics company that was successfully listed on the National Equities Exchange and Quotation (NEEQ).
Dr. Zhu received a PhD from Fudan University and completed a post-doctoral fellowship at Harvard Medical School before receiving his MBA from Chicago Booth.
Robert Altman (Moderator) '88
Adjunct Professor of Entrepreneurship, The University of Chicago Booth School of Business
Professor Robert Altman is an Adjunct Professor of Entrepreneurship at Chicago Booth and Entrepreneur-in-Residence at the Polsky Center. An accomplished healthcare industry executive, Altman's career reflects success in executive roles in both mature and emerging biotech and pharmaceutical businesses.
Most recently, he served as President of Pinnacle Biologics, Inc., a subsidiary of Concordia Healthcare. Altman also previously co-founded and built a fully integrated specialty pharmaceutical company, Marathon Pharmaceuticals, and led the company as CEO and President from 2008 to 2012. His earlier career included numerous leadership positions over 17 years at Abbott Laboratories.
He currently serves on the board of directors for Toltec Pharmaceuticals, a pipeline pharmaceutical company developing novel therapies that address niche markets exclusive to women's health. He is an advisor to Preora Diagnostics, a diagnostics company developing low-cost, minimally invasive, and highly-sensitive cancer pre-screening tests using technology that detects and measures cellular changes at the nanoscale level. He is also an advisor to ThinkLive, Inc, a digital music startup that delivers school based programming that addresses the STEM competency needs of middle school students.
Altman earned an MBA in Finance and Marketing from Chicago Booth, having earlier received both a PhD in Physical Chemistry and an MA in Chemistry from Harvard University, and a BS in Chemistry from the University of California, Riverside. He teaches a five-week course at the University of Chicago Booth School of Business on Entrepreneurship for Science and Medicine.
Dave Chenn (Speaker) '00
Founder, CEO, Managing Partner, Oceanpine Capital
Dave Chenn is the CEO and managing partner of Oceanpine Capital. Previously in 2005, Mr. Chenn founded China Century Group and its several subsidiary companies, a large multinational company today, in the areas of technology, finance, energy, tourism and healthcare in major regions of China, Southeast Asia and United Sates. Prior to it, Mr. Chenn had worked as a head of Oracle's Great China Region Government Industry, director of product management/ marketing in Oracle's Silicon Valley headquarters for five years, as well as at McKinsey and Emerson Electric in Chicago.
Mr. Chenn also serves as both a council member and a global leaders group member of Booth Business School of the University of Chicago, trustee of Culver Academies, Culver, Indiana; Vice Chairman of China Green Energy Fund; Vice Chairman of the Board of Directors at Beijing Institute of Technology, and trustee of Beijing Film Academy. With his philanthropy contribution of over $30 million and the great success of his entrepreneurship, he has been awarded as "Top Ten Reformer of China's Growth in 2017", "Innovation Leader of China's Economy in 2016", among many others, and has been received by the top leaders of China several times.
Mr. Chenn holds an MBA from University of Chicago Booth Business School, and a BS from Beijing Institute of Technology, China.
Bala Srinivasan SM '91, PHD '95 (Speaker)
Senior Advisor to the President, The University of Chicago
In his role as Senior Advisor, Bala Srinivasan works closely with President Zimmer to help drive and support the broad and expanding reach of University of Chicago's science, technology, and innovation efforts, works with deans, officers, laboratory directors, faculty, partners, and members of the President's and Provost's offices in helping to coordinate and integrate the collective science and technology activities, their external representation, and support at the University of Chicago.
Previously, as the Executive Vice President for Science, Innovation, and Strategy, and Deputy Provost, Srinivasan worked with University leadership and faculty in science, engineering and technology to help coordinate and integrate the collective science, engineering and technology activities, their external representation, and support at the University. In addition, he oversaw University efforts in growing programs and presence with non-traditional students, advanced leadership development programs across various levels of University administration and worked with the Dean of the Booth School to provide oversight of entrepreneurship and innovation activities at the Polsky Center.
As Chief International Officer, Srinivasan worked with faculty and staff leadership to oversee the University's global locations and programs, and to strengthen the University's connections with foreign partners.
Prior to joining the University, Srinivasan served as Managing Director of Och Ziff Capital Management, based in India and Hong Kong; Executive Director of Goldman Sachs Hong Kong; and Associate Director of Jardine Fleming in Singapore, Hong Kong, and Mumbai. He received a B.S. in mathematics from Caltech in 1989 and a Ph.D. in mathematics from the University of Chicago in 1995.